Rakuten Medical

Rakuten Medical is a global clinical-stage biotechnology company developing and commercializing precision-targeted investigational therapies on its Illuminox™ platform, which has been shown in preclinical studies to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not been approved by any regulatory authority as safe or effective. The first drug developed on the Illuminox platform, ASP1929, has received approval from Japan's Ministry of Health, Labour, and Welfare and is currently in global Phase 3 clinical trials for recurrent head and neck cancer. With a mission to conquer cancer, Rakuten Medical is committed to enabling cancer patients to lead fulfilling lives. The company has six offices across five countries, including the United States, Japan, the Netherlands, Taiwan, and Switzerland.